The InFUSE™ platform is designed with manufacturability in mind, utilizing GMP-compliant, scalable production processes and quality control measures to ensure consistent and reliable manufacturing of every FUSE vector. The modular vector design allows for flexibility in customization with a multitude of therapeutic payloads and enabling rapid adaptation to evolving cancer targets and patient needs, while also sensitizing tumors to other immunotherapies through the unique mechanism of action. Efficacy of the platform has already been demonstrated preclinically in mulitple predictive solid tumor models, cell lines and primary patient-derived organoids, including those derived from liver, pancreatic, lung and breast cancers.
With these key features, InFUSE™ is a versatile and potent platform that will revolutionize immunotherapy by fighting cancer through fusion.

Looking ahead, Fusix Biotech is committed to advancing the frontiers of cancer immunotherapy through ongoing research and development efforts. We envision an R&D pipeline including the development of indication-targeted constructs, vectors containing novel therapeutic cargo, companion diagnostics, and combination therapies. To achieve this, we welcome opportunities to partner with industry leaders or academic institutions to accelerate these advancements and maximize the impact of our therapies. We also offer potential out-licensing and investment opportunities.

Contact us for more information.